BridgeBio Pharma Inc (BBIO)
30.10
-0.94
(-3.04%)
USD |
NASDAQ |
May 17, 16:00
30.10
0.00 (0.00%)
After-Hours: 20:00
BridgeBio Pharma Cash from Operations (Quarterly): -219.54M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -219.54M |
December 31, 2023 | -124.82M |
September 30, 2023 | -145.23M |
June 30, 2023 | -113.35M |
March 31, 2023 | -144.32M |
December 31, 2022 | -93.24M |
September 30, 2022 | -135.16M |
June 30, 2022 | -30.45M |
March 31, 2022 | -160.64M |
December 31, 2021 | -133.90M |
September 30, 2021 | -121.56M |
June 30, 2021 | -91.71M |
March 31, 2021 | -150.76M |
Date | Value |
---|---|
December 31, 2020 | -96.26M |
September 30, 2020 | -131.68M |
June 30, 2020 | -87.85M |
March 31, 2020 | -83.92M |
December 31, 2019 | -76.20M |
September 30, 2019 | -50.00M |
June 30, 2019 | -68.25M |
March 31, 2019 | -59.14M |
December 31, 2018 | -46.41M |
September 30, 2018 | -38.32M |
June 30, 2018 | -33.96M |
March 31, 2018 | -17.95M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-219.54M
Minimum
Mar 2024
-30.45M
Maximum
Jun 2022
-112.94M
Average
-117.46M
Median
Cash from Operations (Quarterly) Benchmarks
Pfizer Inc | 1.09B |
Alnylam Pharmaceuticals Inc | -81.52M |
Regenxbio Inc | -55.46M |
ACADIA Pharmaceuticals Inc | 29.08M |
Biomarin Pharmaceutical Inc | 46.97M |
Cash from Operations (Quarterly) Related Metrics
Cash from Investing (Quarterly) | 22.75M |
Cash from Financing (Quarterly) | 279.55M |
Free Cash Flow | -605.72M |
Free Cash Flow Per Share (Quarterly) | -1.237 |
Free Cash Flow to Equity (Quarterly) | -210.23M |
Free Cash Flow Yield | -11.89% |